A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors such as pembrolizumab, ipilimumab, and nivolumab, now FDA-approved for use in treating several types of cancer, have been associated with immune-related adverse effects. Specifically, the antibodies targeting the programmed-cell death-1 immune checkpoint, pembrolizumab and nivolumab, have been rarely reported to induce the development of type 1 diabetes mellitus. Here we describe a case of a patient who developed antibody-positive type 1 diabetes mellitus following treatment with pembrolizumab in combination with systemic chemotherapy for metastatic adenocarcinoma of the lung. We will also provide a brief literature review of other rarely reported cases of type 1 diabetes presenting after treatment with pembrolizumab and nivolumab, as well as discussion regarding potential mechanisms of this adverse effect and its importance as these drugs continue to become even more widespread.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [116]
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 649
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Genetics of the HLA Region in the Prediction of Type 1 Diabetes
Noble, J. A., & Valdes, A. M. (2011) · Current Diabetes Reports · doi:10.1007/s11892-011-0223-x · Cited by 460
He, J., Hu, Y., Hu, M., & Li, B. (2015) · Scientific Reports · doi:10.1038/srep13110 · Cited by 401
CD28, CTLA‐4 and their ligands: who does what and to whom?
Sansom, D. M. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00121.x · Cited by 362
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Cited by
Items 101–121 of 121
Matsumoto, N., IWASAKI, H. O., Sasai, Y., Aono-Soma, N., & Sekiya, M. (2025) · Cureus · doi:10.7759/cureus.91593 · Cited by 1
Olivares-Hernández, A., Cornejo, R. A. E., García-Domínguez, A. R., & Cruz, J. J. (2020) · Asian Journal of Oncology · doi:10.1055/s-0040-1710147 · Cited by 1
Mechanisms of Immune-Related Adverse Events
Patil, P. D., & Velcheti, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67241-2.00017-3 · Cited by 1
Managing Checkpoint Inhibitor Symptoms and Toxicity
Pavlick, A. C., & Weber, J. S. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_60-1
Cancer Immunotherapy Related Endocrine Adverse Effects
Kim, H., Cho, S. W., & Park, Y. J. (2019) · International Journal of Thyroidology · doi:10.11106/ijt.2019.12.2.97
Surgery, Chemotherapy, and Radiotherapy for Gynaecological Cancer
Pantazis, K. D., Andronikidis, I., Nikiforidis, L., Floquet, A., & Dinas, K. D. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-4213-2.ch024
Avances y perspectivas actuales en recursos y estrategias terapéuticas: fármacos biológicos
Martín, A. P., Escudero, J. B., Girón, S. H., & Gómez, A. P. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.05.002
Charles, S., & Poullard, A. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon-2122
“These immunomodulating agents have contributed to immune‐related adverse events (irAEs) such as insulin‐dependent Type 1 diabetes (IDDM) which may be life‐threatening, if not promptly recognized by advanced practice registered nurses (APRNs).([3]) Case Report”
BackgroundThe immunoregulation of autoimmune diabetes
Hu, H. (2021) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/3sz5-xf29
Carboplatin/paclitaxel/pembrolizumab
(2017) · Reactions Weekly · doi:10.1007/s40278-017-26374-y
Charles, S., & Poullard, A. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/2347-5625.314467
徐, 慧. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133469
Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.
Qiu, J., Luo, S., Yin, W., Li, X., & Zhou, Z. (2023) · PubMed Central · doi:10.11817/j.issn.1672-7347.2023.220290
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2023) · doi:10.2337/figshare.22373224
Wu, L., Tsang, V., Menzies, A. M., Sasson, S. C., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., & Gunton, J. E. (2023) · doi:10.2337/figshare.22373224.v1
Cancer immunotherapy-associated endocrine complications and treatment strategies
Sen, K., Adhikari, M., Biswas, C., Maity, S., Chatterjee, A., & Pramanick, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00010-8
CTLA-4 Inhibitors for the Treatment of Lung Cancer
Bhatt, S., Sharma, S., Patil, S., & Pujari, R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_6
Talab, T. J., Shafi, F. A. A., & Jasim, S. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.377 · Cited by 2
Ashfaq, F., Alawadi, F., Bashier, A. M., & Ahamed, F. (2026) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0046-1825859
Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review
Sun, S., Su, L., Ma, X., & 窦建新 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1958726 · Cited by 1
Metadata
- Authors
- Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F.
- Affiliations
- Northwestern University (US)
- University of Virginia (US)
- Corresponding author
- Chae, Young Kwang
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2016-10-19
- Volume
- 66
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11028603
- OpenAlex
- W2532961791
- Cited by
- 121
- References
- 34
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 15 · 2020: 16 · 2019: 18 · 2018: 18 · 2017: 20
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- pembrolizumab, type 1 diabetes, immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, nivolumab, ipilimumab, lung adenocarcinoma, metastatic cancer, systemic chemotherapy, autoimmune diabetes, drug-induced diabetes
- MeSH terms
- Aged, Antineoplastic Combined Chemotherapy Protocols, Diabetes Mellitus, Type 1, Humans, Lung Neoplasms, Male, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.